Company

Tubulis

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · PHASE 1/2 TRIAL

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

ClinicalTrials.gov

First-in-human Phase 1/2 trial of a novel agent in early-stage development; no results posted; designed to establish safety, tolerability, and maximum tolerated dose rather than efficacy.

PreliminaryTubulis HNSCC TUB-030

Reported

Planned enrollment250

Trial phasePhase 1/Phase 2

Primary outcome measureDetermination of maximum tolerated dose (MT…

SEP 9, 2026 · PHASE 2 TRIAL

Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer

ClinicalTrials.gov

This is a planned Phase 2 interventional trial with no results posted; it is in pre-recruitment stage and represents early-phase development of TUB-040 in NSCLC.

PreliminaryTUB-040 Tubulis NCT07806773

Reported

Planned enrollment80

PhasePhase 2

Primary outcome 1: Treatment-emer…Enrollment until 30 days after last dose

AUG 17, 2026 · PHASE 1/2 TRIAL

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

ClinicalTrials.gov

This is a first-in-human Phase 1/2 study still in recruitment with no results posted; it aims to establish safety, pharmacokinetics, and preliminary efficacy of a novel antibody-drug conjugate.

PreliminaryTUB-040 Tubulis NCT06303505

Reported

Planned enrollment250

Primary outcome measureDetermination of MTD, from enrollment until…

Dosing intervalEvery 3 weeks